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 ABSTRACT 
 Liver transplantation is the ultimate treatment for patients with end-stage liver diseases. 
Among the primary diagnosis of pediatric liver transplant candidates, biliary atresia is the most 
common cause of liver failure. In this study, we aimed to identify factors associated with 
marginal posttransplant survival among pediatric liver transplant recipients with primary 
diagnosis of biliary atresia. The main event of interest was time from transplant to death. 
Retransplantation was the competing event and alive at the study cutoff was indepenent 
censoring. We analyzed data using five different competing risks regression models and 
compared the results. These models include Cox proportional hazards (PH) model treating 
competing events as censoring, Cox PH model treating competing events as the main event, Fine 
and Gray proportional subdistribution hazards model, random signs censoring regression model, 
and the joint model of time to the main event and time to the competing event. The assumptions 
of each method are described in this thesis. Joint model was used as the gold standard in our 
analysis and the results obtained from other methods were compared to the gold standard. Our 
analysis showed that Cox PH model treating competing event as censoring gave similar results as 
those obtained from the joint model. On ventilator or not, allocation type, split or nonsplit organ, 
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presence of ascites, and presence of portal vein thrombosis at treatment were the risk factors for 
marginal posttransplant survival among pediatric patients with biliary atresia. 
Public health significance: Risk factors of marginal posttransplant survival can be identified 
only if a regression model with appropriate assumption of the dependence structure between the 
event of interest and the competing events is used. We compare the results from three commonly 
used and two newly developed survival regression models for data with competing risks. The 
underlying assumptions of the dependence of the events and the pros and cons of these models 
are described and discussed. Our findings will help a researcher to appropriately choose a 
regression model to identify risk factors when competing risks are present in the data. 
 v 
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1.0  INTRODUCTION 
Liver transplantation (LT) is the ultimate treatment for patients with end-stage liver diseases. 
Among the primary diagnosis of pediatric liver transplant candidates, biliary atresia (BA) is the 
most common cause of liver failure. 
BA is a progressive cholangiopathy disorder of infants, characterized by biliary 
obstruction of unknown pathogenesis. This panbiliary disease affects both the intrahepatic and 
extrahepatic biliary trees and can lead to early development of secondary biliary cirrhosis. 
Incidence of BA varies from one in 8,000 to 18,000 live births. The prognosis for untreated BA 
remains extremely poor, with a patient’s median survival ranging from 8 to 16 months. [1-3] 
Although there exists some treatment methods to improve survival of the native liver, LT 
remains the only effective treatment for patients with end-stage BA. After LT, patients still have 
to overcome challenges in fighting with infection, rejection, and a series of complications. 
Unfortunately, 9% to 29% of pediatric LT recipients require retransplantation which offers the 
only chance for survival when a transplanted liver fails. [4] 
 To study the survival of pediatric liver transplantation, retransplantation is an important 
issue which prevents the occurrence of the main event, death. This issue refers to competing risk 
in the survival analysis, characterized that individuals experience either the main event (death, 
T1) or the competing event (retransplantation, T2).  Method selection in analyzing data with 
competing risks depends on different purpose and assumptions. In this thesis, we will focus on 
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analyzing covariate effects on marginal survival, that is, probability of death in the absence of 
competing risks. Under this situation, dependence structure between the failure times (main 
event and competing events) is needed. When the competing event is independent of the main 
event, e.g. death from the disease of interest and death from traffic accident, the competing event 
can be treated as random censoring, as in Cox Proportional Hazards (PH) model, which is the 
most common used method in competing risk analysis. [5] In another situation, when the 
competing event and main event are related. For example, patients on the wait list of 
retransplantation are in high risk of dying. In this case, it is also reasonable to treat competing 
event as the main event by Cox PH model; the relationship between competing event and main 
event is perfectly positive. Another common used method is Fine and Gray model based on the 
cumulative incidence function (CIF). [6] Although this model is applicable to analyzing crude 
probability, the probability of the occurrence of the main event in the presence of competing 
risks, it can also be viewed as a model of marginal survival probabilities in which the main event 
is considered never happen when the competing event occurs. For example, death is a competing 
event for relapse of breast cancer. The effort to reduce death may adversely affect the risk of 
relapse. Moreover, patients who die from breast cancer cannot be at further risk of relapse; 
therefore in this case the competing event can be treated as perfectly negatively related to the 
main event. In another scenario, when the competing event is a protective approach to avoid the 
observation of the main event, e.g. retransplantation and death, a newly developed method, 
random signs censoring (RSC), is applicable in this situation. [7] Since the competing event and 
main event may not be independent, we constructed a joint model to investigate the association 
of the competing event and main event. [8] 
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To date, only a few published works that address the competing risks approach in 
analyzing posttransplant survival for pediatric liver transplantation. Chardot et al. reviewed 588 
BA patients performed LT between the years 1986 and 2009 in France. Although the 
retransplantation rate was 15.3%, indicating that 90 among 588 recipients underwent more than 
one LT, the study did not consider retransplantation as a competing event in the Cox PH model. 
[9] Utterson et al. studied 755 children with BA listed for their first LT from May 1995 to June 
2003. A competing-risk analysis was used to assess the likelihood of death while waiting, death 
after LT, and death after retransplantation. In their analysis of posttransplant survival, 
retransplantation was treated as a covariate, rather than a competing outcome, in the cause-
specific Cox proportional hazards model. [10] 
In this study, we aim to identify factors associated with marginal posttransplant survival 
among pediatric LT recipients with primary diagnosis of biliary atresia, and to compare the 
results from competing risks models which were constructed under different association 
assumption of main event of interest and competing events. 
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2.0  METHODS 
2.1 DATA 
The data used in this study was extracted from the Standard Transplant Analysis and Research 
(STAR) of the United Network of Organ Sharing (UNOS), which includes all liver transplant 
recipients in United States who were on the transplant waiting list between February 28, 2002 
and June 20, 2010. We removed transplant recipients who were 18 years or older at the time of 
listing, and further excluded patients who eventually received multi-organ transplantation or who 
received LT before listing (n=3,471). Based on the cause of liver failure, we selected patients 
whose primary diagnosis were biliary atresia (n=1,489). During the data checking and cleaning 
phase, one transplant recipient was excluded due to large number of missing values. Finally, a 
cohort of 1,488 pediatric liver transplant recipients with primary diagnosis of biliary atresia was 
included in the analysis. 
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Figure 1. Flowchart of data selection 
2.2 COVARIATES 
Among hundreds of variables in the raw data, we selected 26 relevant variables as our potential 
covariates, which can be divided into the following three different types: 
Recipient characteristics: demographics (age at the time of transplant, gender, and 
race); blood type; presence of portal hypertensive bleeding before transplant; laboratory tests at 
the time of transplantation (serum albumin, total bilirubin, International Normalized Ratio [INR], 
and creatinine), split or nonsplit organ, on ventilator or not, presence of encephalopathy, 
presence of ascites, presence of portal vein thrombosis, presence of spontaneous bacterial 
peritonitis, positive cytomegalovirus (CMV) test, growth failure or not, and region of transplant 
center. 
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Donor characteristics: demographics (age, gender, and race), blood type, donor type 
(cadaveric or living), distance from donor hospital to transplant center, and allocation type (local, 
regional, or others). 
Recipient-donor match variables: blood type compatibility. 
2.3 MODELS 
In this section, we introduce the models that will be used in analyzing marginal postransplant 
survival. Suppose there are n  independent patients included in the study, and k competing 
events ( 1k = indicating the main event and 2k = indicating competing events). Let iT , 1,...,i n=  
be the failure time with respect to subject i . The observed values for individual i
include{ , , }i i iX Zδ , where iX is the observed failure time; 0,1, 2iδ =  is the event indicator for 
censoring, main event, and competing event, respectively; and iZ  is a p-dimensional vector of 
covariates. 
Cox Proportional Hazards Model 
Cox PH model is a widely used semiparametric survival regression model based on the 
PH assumption. Let ( | )k t Zλ be the kth cause-specific hazard rate at time t with risk vector Z for 
an individual. The Cox PH model has the following form: 
,0( | ) ( ) exp( )
T
k kt Z t Zλ λ β= ,        (2.3.1) 
where ,0 ( )k tλ is an unknown baseline hazards rate for cause k; and ( )1, , pβ β β ′= … is a vector of 
unknown regression parameters. The hazard ratio (HR) of two individuals with covariate values 
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Z and Z* can be derived as HR = 
1
( | ) exp[ ( * )]
( | *)
p
k k k
k
t Z Z Z
t Z
λ β
λ =
= −∑ . The unknown regression 
coefficients β are estimated by the score equation 
** *
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( ) { ( , )} ( )
n
i i
i
U Z Z t dN t
τ
β β
=
= −∑∫ ,           (2.3.2) 
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*(1)
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( , )( , )
( , )
S tZ t
S t
ββ
β
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*( ) 1 *
1
( , ) ( ) exp( )
n
k T k
j j j
j
S t n Y t Z Zβ β− ⊗
=
= ∑ , 
*
1 ( )iN t is the indicator function of whether main event occurs for individual i (
*
1 1( ) ( )i iN t I T t= ≤ ), 
*
1 ( )iY t is the indicator function of whether individual i is at risk (
*
1 1( ) ( )i iY t I T t= ≥ ), and τ  is any 
time point greater than the maximum observed main event time. 
In this study, we built two Cox PH models: treating competing risk (retransplantation) as 
an event, and treating competing risk as censoring. The former model assumes that competing 
event is perfectly positively correlated with the event of interest (death), while the later one treats 
retransplantation as independent censoring.  
Fine and Gray Model 
Fine and Gray model is a semiparametric proportional subdistribution hazards model. 
Subdistribution is defined as the cumulative incidence function (CIF) for the corresponding 
cause of failure, i.e., the probability of experiencing a particular cause of failure up to time t, in 
the presence of all the other possible causes. The CIF at time t for cause j can be written as the 
form: 
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0
( ) ( , ) ( ) ( )
t
k kF t P X t j h u S u du     .                               (2.3.3) 
The hazard of subdistribution is a function of the cumulative incidence and can be 
represented as: 
log(1 ( ))
( ) kk
d F t
t
dt


  .                                             (2.3.4) 
Given a vector of risk factors Z, the Fine and Gray model of the subdistribution hazards 
for cause k has the form  
,0( | ) ( )exp( )
T
k k kt Z t Z   ,                                       (2.3.5) 
where ,0 ( )k t is the baseline subdistribution hazards function; and k  is a vector of unknown 
regression parameters. As the cumulative incidence defined and treating it as a marginal 
probability, the event of interest and the competing events can be viewed as perfectly negatively 
associated because the event of interest would never occur if one of the k competing events 
happened. 
 
Random Signs Censoring Model 
Random signs censoring (RSC) posits that the potential failure time of the event of 
interest is independent of the sign: competing event happens before the main event. There exists 
a signal prior to failure, for example, failure of the transplanted organ, leading to some actions to 
prevent the occurrence of the main event, e.g. death. The RSC assumption requires that the 
normalized subdistribution function of the main event is stochastically lower than that of the 
competing event. It can be checked from the survival curves, showing that the curve of main 
event is above that of competing event (
1 2( ) ( )S t S t ). Let T1 be the failure time of the main 
event and T2 be the failure time of the competing event. Suppose T1 follows a Cox PH model. 
Then, the hazard *1 ( | )t Zλ of T1 has the form
* *
1 10( | ) ( ) exp( )t Z t Zλ λ β ′= . If data does not contain 
independent right censoring, unknown regression parameters β can be estimated by the partial 
likelihood estimating equation (2.3.2) by removing individuals with competing events from the 
dataset. When data contains independent right censoring, the estimating equation of the RSC 
regression model incorporates inverse probability of censoring weights (IPCW): 
0
1
( ) { ( , )} ( )
( )
n
i
i i
i i
U Z Z t dN t
G X
τ δ
β β
=
= −∑∫ , (2.3.6) 
where ( )I T Cδ = ≤ , C is the random variable of censoring time which assumed to be 
independent of T1 and T2; ( ) Pr( )G t C t= > is the underlying survival distribution of C;  
(1)
(0)
( , )( , )
( , )
S tZ t
S t
ββ
β
= ; 
( ) 1
1
1
( , ) ( ) exp( )
( )
n
jk k
j j j j
j j
S t n Y t Z Z
G X
δ
β ε β− ⊗
=
′= ∑ ; 
ε1 = I(T1≤ T2); and X = min(C, T). In practice, G(t) has to be replaced by a consistent estimator 
(e.g., Kaplan-Meier estimator of censoring). 
Joint Modeling 
Joint modeling method was used to account for informative dropouts. Basically, it jointly 
models the process of the time to the main event of interest, and the process of the dropouts due 
to competing risks. The dependence between the main event and competing risks is captured via 
random effects terms. The likelihood function of the joint model with shared random effects has 
the following form: 
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1 1
( ; , , , , ) ( ; , | ) ( )
i
n
i ki k k i i k ki ki i i iv
i k
L T Z l T Z f dβ λ θ υ υ υ υ
= =
= Ω∏ ∏∫ ,                 (2.3.7) 
where ( )if υ is the probability density function of the random terms iυ ; 0{ , , }k kβ λ θΩ = ; θ is a 
vector of parameters in the density function of the random terms, and 2θ σ= when assuming the 
random terms iυ  follows a normally distribution with mean zero and standard deviation 
2σ ; kl denotes the marginal likelihood function of event k with the following form 
0
( | ) { ( | )} exp{ ( ( | ) }ki
t
k i ki i ki il t t t dt
δυ λ υ λ υ= −∫ . (2.3.8) 
The hazards function specified here is assumed to follow a proportional hazards two-
parameter Weibull distribution with baseline hazards function of the form: 
1 ( 2)( ) exp{ }T I kki k ki it t Z
αλ λα β φ υ− == + ,                                 (2.3.9) 
where ( 2)I k =  is an indicator function of competing event (k = 2); theλ and α are the scale and 
shape parameters, respectively; and φ  is the coefficient of the shared random effect term, which 
reflecting the direction of the association between the main event and competing event. The main 
challenge of parameter estimation is the multidimensional integration towards the random terms. 
The Gaussian quadrature method can be used to solve the estimating equations. 
In modeling marginal survival for data with competing risks, it is important to make 
assumptions about the dependence structure between the potential failure times. Peterson (1976) 
states that there exist lower and upper bounds for the marginal survival function ( )iS t , when the 
risks are dependent. [11] When the competing event is equivalent to the main event, the marginal 
survival function ( )iS t becomes the total survival function ( )TS t . On the other hand, when the 
risks are perfectly negatively related, the marginal survival function ( )iS t becomes one minus the 
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cumulative incidence function,1 ( )iF t− . These lower and upper bounds can be achieved if we 
analyze data using a Cox PH model treating competing events as the main event and using a Fine 
and Gray model, respectively.  
2.4 STATISTICAL ANALYSIS 
We first checked each variable for missing values, and removed variables from the candidate list 
if they had great amount of missing. Recipients age was divided into three groups, less than one, 
one to two, and greater than two years old; while Donors age was categorized into less than one 
and greater than or equal to one years old. Dummy variables were created for categorical 
variables, e.g. recipients’ race of white or other, CMV test positive or negative, on ventilator or 
not at the time of transplant, etc.  
Variables retained were included in the univariable analysis which consists of five 
models. The results of univariable analysis were used to select variables into the final 
multivariable model if a variable was significant at the level of 0.15 in at least one model among 
the five. To compare the differences of the models, we fit the five models using the same set of 
selected variables. As the sensitivity test, we repeated the univariable and multivariable analysis 
steps restricted only to patients received cadaveric liver transplants. All data management and 
analysis were implemented in SAS 9.3 and R version 2.14.1. 
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3.0  RESULTS 
3.1 DESCRIPTIVE ANALYSIS 
Table 1 shows the descriptive statistics for the covariates considered in the univariable analysis. 
Among 1,488 LT recipients, 93 (6.25%) died, 127 (8.53%) received retransplantation, and the 
rest 1,268 (85.23%) were alive at the study cutoff date. The median follow-up time was 764 days 
(approximately 2.09 years). 
In the initially selected variables (see Section 2.2), three of them were excluded due to 
large percentage of missing values: presence of portal hypertensive bleeding before transplant 
(missing=998, 67.1%), presence of spontaneous bacterial peritonitis at transplant (missing=703, 
47.2%), and growth failure or not (missing=139, 9.3%). Moreover, encephalopathy was removed 
because of collinearity with positive CMV test.  
Table 1. Characteristics of the covariates considered in the univariable models 
Characteristics 
All Recipients Patient Outcome 
(N = 1488) Alive Retransplant Died 
(N = 1268) (N = 127) (N = 93) 
Recipient Characteristics 
Time follow-up, median, 
mean ± SD(days) 764, 981 ± 822 1069, 1107 ± 805 15, 243 ± 451 27, 275 ± 487 
Demographics 
Age, median, mean ± SD 
(years) 0, 1.88 ± 3.66 0, 1.97 ± 3.75 0, 1.51 ± 3.37 0, 1.09 ± 2.50 
Gender, No. (%) 
Female 852 (57.26) 720 (56.78) 76 (59.84) 56 (60.22) 
Male 636 (42.74) 548 (43.22) 51 (40.16) 37 (39.78) 
Race / ethnicity, No. (%) 
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White 721 (48.45) 606 (47.79) 70 (55.12) 45 (48.39) 
Other 767 (51.55) 662 (52.21) 57 (44.88) 48 (51.61) 
Medical/Clinical Covariates 
Blood type, No. (%) 
A 510 (34.27) 432 (34.07) 49 (38.58) 29 (31.18) 
AB 70 (4.70) 63 (4.97) 5 (3.94) 2 (2.15) 
B 190 (12.77) 166 (13.09) 9 (9.68) 9 (9.68) 
O 718 (48.25) 607 (47.87) 58 (45.67) 53 (56.99) 
On ventilator, No. (%) 
Yes 64 (4.30) 56 (3.63) 6 (4.72) 12 (12.90) 
No 1424 (95.70) 1222 (96.37) 121 (95.28) 81 (87.10) 
Laboratory values, Median , Mean ± SD  
Albumin (g/dl) 3.0, 3.03 ± 0.77 3.0, 3.03 ± 0.78 3.0, 3.01 ± 0.66 3.0, 3.01 ± 0.72 
Bilirubin (mg/dl) 10.9, 12.75 ± 10.63 10.8, 12.71 ± 10.67 8.1, 11.30 ± 9.49 13.5, 15.38 ± 11.20 
Serum creatinine 
(mg/dl)* 0.3, 0.33 ± 0.26 0.3, 0.33 ± 0.27 0.3, 0.31 ± 0.23 0.3, 0.30 ± 0.20 
INR 1.4, 1.74 ± 2.61 1.4, 1.75 ± 2.80 1.4, 1.67 ± 1.08 1.5, 1.74 ± 0.96 
Positive cytomegalovirus (CMV) test, No. (%) 
Yes 482 (32.39) 415 (32.73) 38 (29.92) 29 (31.18) 
No 1006 (67.61) 853 (67.27) 89 (70.08) 64 (68.82) 
Presence of ascites, No. (%) 
Yes 730 (49.06) 603 (47.56) 71 (55.91) 56 (60.22) 
No 390 (26.21) 351 (27.68) 23 (18.11) 16 (17.20) 
Unknown 368 (24.73) 314 (24.76) 33 (25.98) 21 (22.58) 
Presence of portal vein thrombosis, No. (%) ** 
Yes 53 (3.62) 41 (3.29) 5 (3.97) 7 (7.53) 
No 1362 (93.10) 1166 (93.65) 116 (92.06) 80 (86.02) 
Unknown 48 (3.28) 38 (3.05) 5 (3.97) 6 (6.45) 
Previous abdominal surgery, No. (%) ** 
Yes 1077 (73.62) 921 (73.98) 87 (69.05) 69 (74.19) 
No 336 (22.97) 281 (22.57) 34 (26.98) 21 (22.58) 
Unknown 50 (3.42) 43 (3.45) 5 (3.97) 3 (3.23) 
Other Characteristics 
Donor type, No. (%) 
Deceased 1250 (84.01) 1053 (83.04) 114 (89.76) 83 (89.25) 
Living 238 (15.99) 215 (16.96) 13 (10.24) 10 (10.75) 
Donor age, median, mean ± 
SD (years) 8, 12.19 ± 12.71 9, 12.43 ± 12.63 2, 9.25 ± 12.70 9, 12.83 ± 13.36 
Donor gender, No. (%) 
Female 707 (47.51) 603 (47.56) 56 (44.09) 48 (51.61) 
Male 781 (52.49) 665 (52.44) 71 (55.91) 45 (48.39) 
Donor race / ethnicity, No. (%) 
White 863 (58.00) 736 (58.04) 76 (59.84) 51 (54.84) 
Other 625 (42.00) 532 (41.96) 51 (40.16) 42 (45.16) 
Donor blood type, No. (%) 
A 499 (33.53) 427 (33.68) 47 (37.01) 25 (26.88) 
AB 26 (1.75) 24 (1.89) 1 (0.79) 1 (1.08) 
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Table 1. Continued
B 160 (10.75) 135 (10.65) 16 (12.60) 9 (9.68) 
O 803 (53.97) 682 (53.79) 63 (49.61) 58 (62.37) 
ABO compatible, No. (%) 
Yes 1448 (97.31) 1232 (97.16) 124 (97.64) 92 (98.92) 
No 40 (2.69) 36 (2.84) 3 (2.36) 1 (1.08) 
Transplantation Related Characteristics 
Center location (region), No. (%) 
1: CT, ME, MA, NH, 
RI 42 (2.82) 41 (3.23) 0 (0.00) 1 (1.08) 
2: DC, DE, MD, NJ, 
PA, WV 150 (10.08) 128 (10.09) 17 (13.39) 5 (5.38) 
3: AL, AR, FL, GA, 
LA, MS, PR 188 (12.63) 154 (12.15) 19 (14.96) 15 (16.13) 
4: OK, TX 156 (10.48) 125 (9.86) 17 (13.39) 14 (15.05) 
5: AZ, CA, NV, NM, 
UT 324 (21.77) 287 (22.63) 23 (18.11) 14 (15.05) 
6: AK, HI, ID, MT, 
OR, WA 32 (2.15) 29 (2.29) 2 (1.57) 1 (1.08) 
7: IL, MN, ND, SD, WI 126 (8.47) 104 (8.20) 13 (10.24) 9 (9.68) 
8: CO, IA, KS, MO, 
NE, WY 149 (10.01) 128 (10.09) 13 (10.24) 8 (8.60) 
9: NY, VT 94 (6.32) 79 (6.23) 10 (7.87) 5 (5.38) 
10: IN, MI, OH 136 (9.14) 116 (9.15) 7 (5.51) 13 (13.98) 
11: KY, NC, SC, TN, 
VA 91 (6.12) 77 (6.07) 6 (4.72) 8 (8.60) 
Allocation type, No. (%) 
Local 700 (47.58) 608 (47.95) 60 (47.24) 40 (43.01) 
Regional 556 (37.37) 476 (37.54) 38 (29.92) 42 (45.16) 
Other 224 (15.05) 184 (14.51) 29 (22.83) 11 (11.83) 
Procurement distance,
Median, Mean ± SD (miles) 128, 270 ± 400 124, 268 ± 401 158, 316 ± 448 141, 239 ± 301 
Partial or split donor organ, No. (%) 
Partial or split 699 (46.98) 601 (47.40) 46 (36.22) 52 (55.91) 
Whole 789 (53.02) 667 (52.60) 81 (63.78) 41 (44.09) 
Abbreviation: SD (Standard Deviation). 
* Serum creatinine values were missing for 72 children: 61 alive, 6 retransplanted and 5 dead.
** Both portal vein thrombosis and previous abdominal surgery have missing values in 25 subjects: 23 alive, 1 
retransplanted, and 1 dead.  
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Table 1. Continued
3.2 UNIVARIABLE ANALYSIS 
Table 2 shows the univariable analysis results from the five models. Age of recipients, on 
ventilator, presence of ascites, and presence of portal vein thrombosis were significant in all five 
models at the level of 0.15. For donor age and serum total bilirubin, the Cox PH models with 
retransplant as event had the opposite results with other models. Donor’s age was only 
significant in the former, while bilirubin was significant in the latter ones rather than the former. 
It may be caused by the inflating of sample size of event (death) in the Cox model where 
competing event (retransplant) was also considered as the main event.  
Figure 2 shows the survival curves of main event and competing event without censoring, 
indicating that the RSC assumption is satisfied. However, the RSC univariable models had quite 
different results from other models. Beside of the variables mentioned above, some factors were 
significant with p-value less than 0.15, including recipient race, procurement distance, serum 
creatinine, CMV test positive, and allocation type. Moreover, hazard ratios (HRs) were also 
inconsistent with other models in 7 variables among the 21 factors in total. For example, the HR 
of serum creatinine was no greater than 0.8 in the Cox, Fine and Gray and joint model, while it 
was 5.57 in the RSC model. The joint modeling result showed not only HR, but φ estimates, 
which indicates the relationship between main event and competing event. All theφ estimates 
were greater than zero and p-values were larger than 0.05, indicating a non-significant positive 
association of death and retransplantation in this data. 
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Figure 2. Check the RSC assumption: Survival curves for death and retransplant 
Table 2. Univariable analysis 
Cox - Retransplant as event Cox - Retransplant as censor Fine & Gray model RSC Joint Modeling 
HR 
95% CI 
p-value HR 
95% CI 
p-value HR 
95% CI 
p-value HR 
95% CI 
p-value HR 
95% CI p-
value 
phi sigma 
LL UL LL UL LL UL LL UL LL UL EST p-value EST
p-
value 
Recipient 
age 
1--2 0.92 0.66 1.26 0.589 0.87 0.53 1.43 0.577 0.87 0.53 1.43 0.590 1.72 1.08 2.74 0.021|| 0.83 0.47 1.45 0.504 1.17 0.198 1.75 0.050 
> 2 0.61 0.42 0.89 0.010|| 0.57 0.32 1.02 0.059|| 0.58 0.33 1.05 0.070|| 1.62 0.94 2.78 0.081|| 0.53 0.27 1.02 0.056|| 
Donor age 0.46 0.34 0.62 <0.001|| 0.75 0.44 1.28 0.292 0.82 0.48 1.40 0.460 0.88 0.55 1.42 0.607 0.78 0.42 1.45 0.435 1.11 0.435 1.80 0.222 
Recipient gender 1.12 0.85 1.47 0.412 1.13 0.74 1.71 0.573 1.12 0.74 1.69 0.590 0.80 0.54 1.17 0.243 
Donor gender 0.98 0.75 1.28 0.903 1.17 0.78 1.76 0.453 1.18 0.79 1.78 0.410 0.91 0.64 1.31 0.624 1.23 0.63 2.40 0.553 0.82 0.846 2.15 0.708 
Recipient race 
(White/Other) 1.17 0.90 1.53 0.243 1.00 0.67 1.50 0.995 0.99 0.66 1.48 0.950 1.38 0.95 2.02 0.094|| 
Donor race 
(White/Other) 0.99 0.75 1.29 0.914 0.88 0.58 1.32 0.528 0.88 0.58 1.32 0.520 1.14 0.79 1.64 0.492 
ABO compatible 1.41 0.52 3.79 0.498 2.40 0.33 17.19 0.385 2.39 0.33 17.30 0.390 0.40 0.06 2.78 0.352 2.28 0.25 20.52 0.461 0.93 0.570 2.01 0.315 
Recipient 
blood type 
A 0.99 0.74 1.32 0.927 0.77 0.49 1.20 0.249 0.76 0.48 1.19 0.230 1.01 0.68 1.51 0.960 0.73 0.43 1.26 0.261 1.06 0.421 1.85 0.191 
B 0.82 0.53 1.27 0.372 0.64 0.32 1.30 0.219 0.64 0.32 1.30 0.220 1.00 0.55 1.84 0.991 0.62 0.28 1.40 0.253 
AB 0.64 0.30 1.36 0.244 0.38 0.09 1.55 0.177 0.38 0.09 1.53 0.170 1.20 0.32 4.48 0.787 0.37 0.08 1.74 0.209 
Donor blood 
type 
A 0.98 0.73 1.31 0.872 0.70 0.44 1.13 0.144 0.70 0.44 1.11 0.130 0.90 0.60 1.36 0.623 0.69 0.40 1.20 0.191 1.08 0.499 1.83 0.277 
B 1.05 0.69 1.62 0.808 0.79 0.39 1.59 0.507 0.78 0.39 1.56 0.480 0.96 0.52 1.75 0.888 0.77 0.34 1.73 0.527 
AB 0.49 0.12 1.98 0.317 0.51 0.07 3.69 0.505 0.52 0.07 3.69 0.510 1.24 0.19 8.05 0.823 0.59 0.07 4.96 0.630 
On ventilator 2.23 1.38 3.62 0.001|| 3.73 2.03 6.84 <0.001|| 3.67 1.98 6.79 <0.001|| 2.61 1.42 4.79 0.002|| 6.18 1.42 26.83 0.015|| 0.91 0.361 2.03 0.108 
Procurement distance 1.00 1.00 1.00 0.411 1.00 1.00 1.00 0.575 1.00 1.00 1.00 0.430 1.00 1.00 1.00 0.048|| 
Albumin 0.96 0.81 1.15 0.659 0.96 0.73 1.26 0.771 0.96 0.74 1.25 0.770 1.00 0.74 1.34 0.984 0.94 0.66 1.34 0.728 0.83 0.678 2.14 0.424 
Bilirubin 1.00 0.99 1.01 0.693 1.02 1.00 1.04 0.016|| 1.02 1.01 1.04 0.007|| 1.00 0.99 1.02 0.654 1.02 1.00 1.04 0.047|| 1.42 0.375 1.51 0.213 
INR 0.99 0.93 1.06 0.867 1.00 0.93 1.08 0.966 1.00 0.97 1.04 0.920 1.02 0.85 1.22 0.819 1.00 0.89 1.13 0.559 0.75 0.661 2.26 0.368 
Serum creatinine * 0.72 0.39 1.33 0.291 0.76 0.30 1.91 0.553 0.78 0.35 1.75 0.550 5.57 1.87 16.66 0.002|| 0.69 0.24 2.00 0.489 1.02 0.252 1.92 0.060 
CMV positive 0.89 0.66 1.18 0.408 0.92 0.59 1.42 0.700 0.93 0.60 1.43 0.730 0.57 0.37 0.86 0.008|| 
Allocation type 
(Local/Other) 0.85 0.65 1.10 0.219 0.76 0.51 1.15 0.197 0.78 0.52 1.17 0.230 0.45 0.30 0.67 <0.001|| 0.67 0.40 1.12 0.130|| 0.97 0.270 1.97 0.059 
Ascites 1.32 1.01 1.72 0.043|| 1.46 0.96 2.22 0.074|| 1.46 0.96 2.21 0.077|| 1.68 1.12 2.50 0.011|| 1.53 0.91 2.58 0.110|| 0.96 0.284 1.98 0.065 
Split donor organ 0.87 0.67 1.14 0.320 1.38 0.92 2.08 0.124 1.42 0.95 2.14 0.091|| 0.58 0.40 0.86 0.007|| 1.33 0.69 2.57 0.397 2.75 0.904 0.91 0.885 
Portal vein 
thrombosis ** 1.58 0.88 2.82 0.125|| 2.23 1.03 4.83 0.041|| 2.21 1.00 4.87 0.050|| 3.49 1.60 7.62 0.002|| 3.27 0.69 11.10 0.057|| 0.88 0.299 2.08 0.057 
Previous abdominal 
surgery ** 0.92 0.69 1.24 0.602 1.10 0.68 1.76 0.699 1.10 0.69 1.77 0.680 0.74 0.48 1.15 0.188 
Abbreviation: CI (Confidence Interval), LL(Lower Limit), UL(Upper Limit), HR(Hazard Ratio), EST(Estimate). 
* Serum creatinine values were missing for 72 children: 61 alive, 6 retransplanted and 5 dead.
** Both portal vein thrombosis and previous abdominal surgery have missing values in 25 subjects: 23 alive, 1 retransplanted, and 1 dead. 
||Statistically significant at the level of 0.15.
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3.3 MULTIVARIABLE ANALYSIS 
Table 3 shows the multivariable analysis results. On ventilation was significant in all 
models, while donor age and presence of ascites were only significant in the Cox model 
with retransplant as the event of interest (Model 1). Fine and Gray (Model 3) shared the 
same list of significant covariates with the Cox model which treated competing event as 
censoring (Model 2), as well as the joint model (Model 5), including on ventilator, 
allocation type, and the presence of portal vein thrombosis. RSC (Model 4) had the 
greatest number of significant covariates than others.  
Most of the HRs in Model 1, 2, 3, and 5 were close to each other, except two 
covariates, on ventilator and the presence of portal vein thrombosis, whose HRs were 
greater in Model 2, 3 and 5 than in Model 1. HRs in Model 4 were far apart from those in 
other models, especially the HR of serum creatinine which changed from 0.6 to 0.8 in 
Model 1 - 3, and to 9.3 in Model 4.  
The estimated φ  from Model 5 was 1.02 with a p-value of 0.054, reflecting a non-
significant positive relationship between retransplant and death. 
Allocation type in Model 1 and presence of portal vein thrombosis in Model 2 
violate the PH assumption, which indicates that HR of the variable varies over time. The 
HR obtained from a proportional hazards regression model gave a weighted average of 
the time-varying HR. We can fit a Gray time-varying coefficients model to check how 
HR changes over time. [12] 
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Table 3. Multivariable analysis 
Cox - Retransplant as event Cox - Retransplant as censor Fine & Gray model RSC - W1 Joint Modeling 
HR 
95% CI 
p-value HR 
95% CI 
p-value HR 
95% CI 
p-value HR 
95% CI 
p-value HR 
95% CI p-
value 
phi sigma 
LL UL LL UL LL UL LL UL LL UL est 
p-
value est 
p-
value 
Recipient 
age 
1 -- 2 0.89 0.62 1.26 0.502 0.91 0.53 1.56 0.732 0.92 0.52 1.63 0.780 1.52 0.85 2.72 0.161 0.89 0.48 1.66 0.719 
1.02 0.054 1.93 0.002 
> 2 0.80 0.52 1.22 0.297 0.86 0.44 1.67 0.658 0.88 0.45 1.70 0.700 1.38 0.64 2.99 0.411 0.79 0.37 1.70 0.554 
Donor age 0.48 0.32 0.71 <0.001|| 0.71 0.36 1.43 0.343 0.75 0.37 1.52 0.430 1.36 0.64 2.87 0.425 0.81 0.37 1.78 0.601 
Recipient race 
(White/Other) 1.22 0.92 1.60 0.168 1.03 0.67 1.58 0.895 1.01 0.65 1.57 0.970 1.02 0.60 1.74 0.944 0.96 0.58 1.57 0.859 
Bilirubin 0.99 0.98 1.00 0.141 1.01 0.99 1.03 0.271 1.01 0.99 1.03 0.230 0.97 0.94 0.99 0.015|| 1.01 0.98 1.03 0.527 
Serum creatinine * 0.84 0.45 1.56 0.575 0.69 0.25 1.85 0.456 0.69 0.29 1.63 0.400 9.31 2.43 35.61 0.001|| 0.61 0.19 1.94 0.399 
Procurement 
distance 1.00 1.00 1.00 0.904 1.00 1.00 1.00 0.180 1.00 1.00 1.00 0.110 1.00 1.00 1.00 0.312 1.00 1.00 1.00 0.107 
On ventilator 2.41 1.44 4.03 0.001|| 3.16 1.62 6.18 <0.001|| 3.12 1.57 6.20 <0.001|| 4.40 2.09 9.23 <0.001|| 5.64 1.86 17.11 0.002|| 
CMV positive 0.97 0.72 1.30 0.832 1.03 0.65 1.62 0.903 1.03 0.65 1.64 0.890 0.76 0.47 1.21 0.241 0.99 0.57 1.72 0.982 
Allocation type 
(Local/Other) 0.87 0.62 1.22 0.433 0.53 0.32 0.90 0.019
|| 0.53 0.32 0.88 0.015|| 0.39 0.20 0.76 <0.001|| 0.42 0.21 0.82 0.011|| 
Ascites 1.36 1.02 1.81 0.033|| 1.38 0.88 2.15 0.156 1.38 0.87 2.18 0.170 1.64 1.00 2.71 0.052 1.53 0.89 2.66 0.127 
Split donor organ 1.12 0.79 1.60 0.524 1.56 0.90 2.71 0.110 1.60 0.93 2.76 0.090 1.45 0.76 2.77 0.256 1.48 0.78 2.80 0.226 
Portal vein 
thrombosis ** 1.42 0.79 2.55 0.247 2.50 1.14 5.48 0.022
|| 2.54 1.11 5.79 0.027|| 5.76 2.32 14.30 <0.001|| 3.88 1.25 12.09 0.019|| 
Abbreviation: CI (Confidence Interval), LL(Lower Limit), UL(Upper Limit), HR(Hazard Ratio), EST(Estimate). 
* Serum creatinine values were missing for 72 children: 61 alive, 6 retransplanted and 5 dead.
** Portal vein thrombosis has missing values in 25 subjects: 23 alive, 1 retransplanted, and 1 dead. 
||Statistically significant at the level of 0.05.
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3.4 SENSITIVITY ANALYSIS 
Data of recipients who had cadaveric donor was included in this sensitivity 
analysis. Among 1250 recipients, there were 83 (6.64%) died, 114 (9.12%) 
retransplanted, and 1,053 (84.24%) were alive at the study cutoff date. Table 4 shows the 
univariable results. Covariate selection was the same as that in models using the entire 
data, although some covariates were significant in sensitivity test and not in the entire 
data study. These covariates included presence of portal vein thrombosis in the Cox 
model with retransplant as event, and split or nonsplit organ in the Cox model with 
retransplant as censoring and in the joint model. In addition, all the univariable models in 
the joint model were converged in the sensitivity analysis.  
Table 5 shows the multivariable results which appeared to have more significant 
covariates than that in the model using entire data. The difference came from two 
covariates, presence of ascites and split organ, which were significant in models with 
recipients of cadaveric organs, but not in the models with all recipients. From the joint 
model, estimated φ  was positive and its p-value was less than 0.05, indicating that 
retransplant and death were significantly positively related. 
20 
Table 4. Sensitivity analysis - univariable analysis 
Cox - Retransplant as event Cox - Retransplant as censor Fine & Gray model Random Signs Censoring Joint Modeling 
HR 
95% CI p-
value HR 
95% CI p-
value HR 
95% CI p-
value HR 
95% CI p-
value HR 
95% CI p-
value 
phi sigma 
LL UL LL UL LL UL LL UL LL UL est 
p-
value est 
p-
value 
Recipient 
age 
1 -- 2 0.86 0.62 1.21 0.395 0.69 0.40 1.20 0.190 0.70 0.40 1.20 0.190 1.79 1.09 2.95 0.022|| 0.63 0.35 1.15 0.134|| 1.36 0.153 1.54 0.048 
> 2 0.54 0.37 0.80 0.002|| 0.49 0.27 0.91 0.023|| 0.51 0.28 0.93 0.029|| 1.93 1.09 3.42 0.025|| 0.45 0.23 0.88 0.019|| 
Donor age 0.49 0.36 0.67 <0.001|| 0.81 0.47 1.39 0.440 0.88 0.51 1.51 0.640 0.83 0.51 1.34 0.443 1.19 0.67 2.12 0.548 1.01 0.237 1.88 0.052 
Recipient gender 1.04 0.78 1.38 0.807 1.06 0.69 1.64 0.789 1.06 0.68 1.64 0.800 0.74 0.49 1.10 0.139 1.04 0.64 1.69 0.889 1.10 0.241 1.78 0.069 
Donor gender 1.01 0.76 1.34 0.951 1.11 0.72 1.71 0.640 1.12 0.73 1.72 0.610 0.85 0.58 1.25 0.409 1.14 0.70 1.86 0.603 1.07 0.251 1.81 0.070 
Recipient race 
(White/Other) 1.21 0.92 1.60 0.178 0.99 0.64 1.52 0.958 0.97 0.63 1.49 0.880 1.47 0.98 2.18 0.061|| 0.97 0.60 1.57 0.889 1.10 0.238 1.79 0.066 
Donor race 
(White/Other) 0.99 0.75 1.31 0.943 0.85 0.55 1.30 0.445 0.84 0.55 1.30 0.430 1.18 0.80 1.73 0.407 0.83 0.51 1.34 0.442 1.12 0.213 1.76 0.057 
ABO compatible 1.44 0.53 3.87 0.472 2.42 0.34 17.40 0.379 2.41 0.33 17.45 0.380 0.36 0.05 2.56 0.309 2.39 0.30 19.20 0.412 1.13 0.231 1.75 0.067 
Recipient 
blood type 
A 1.01 0.74 1.37 0.956 0.73 0.46 1.18 0.201 0.72 0.45 1.16 0.180 0.99 0.65 1.49 0.947 0.71 0.42 1.20 0.198 1.65 0.424 1.32 0.296 
B 0.77 0.48 1.24 0.280 0.52 0.24 1.15 0.107 0.52 0.24 1.15 0.110 1.11 0.56 2.20 0.764 0.52 0.22 1.19 0.123 
AB 0.46 0.19 1.14 0.095 0.19 0.03 1.36 0.097 0.19 0.03 1.34 0.096 1.29 0.20 8.42 0.787 0.20 0.03 1.46 0.112 
Donor blood 
type 
A 0.93 0.69 1.26 0.645 0.62 0.37 1.01 0.056 0.61 0.37 1.00 0.048 0.87 0.57 1.34 0.533 0.59 0.34 1.03 0.065 1.41 0.313 1.49 0.166 
B 0.90 0.56 1.43 0.651 0.60 0.27 1.33 0.211 0.60 0.27 1.32 0.200 1.07 0.54 2.10 0.853 0.60 0.26 1.40 0.237 
AB 0.44 0.11 1.78 0.250 0.44 0.06 3.20 0.420 0.45 0.06 3.22 0.430 1.25 0.19 8.09 0.818 0.50 0.06 3.91 0.505 
On ventilator 2.00 1.18 3.38 0.010|| 2.96 1.48 5.92 <0.001|| 2.90 1.45 5.87 <0.001|| 2.60 1.31 5.19 <0.001|| 4.38 1.39 13.78 0.012|| 0.99 0.184 1.90 0.029 
Procurement distance 1.00 1.00 1.00 0.944 1.00 1.00 1.00 0.306 1.00 1.00 1.00 0.210 1.00 1.00 1.00 0.017|| 1.00 1.00 1.00 0.313 1.02 0.218 1.88 0.044 
Albumin 0.94 0.78 1.13 0.485 0.94 0.71 1.25 0.682 0.94 0.71 1.26 0.690 1.01 0.74 1.37 0.957 0.91 0.64 1.29 0.610 1.09 0.241 1.79 0.067 
Bilirubin 1.00 0.99 1.01 0.763 1.02 1.00 1.04 0.055|| 1.02 1.00 1.03 0.026|| 1.00 0.98 1.02 0.896 1.02 1.00 1.04 0.126 1.41 0.300 1.49 0.154 
INR 0.99 0.93 1.06 0.869 1.00 0.91 1.09 0.931 1.00 0.95 1.04 0.840 1.02 0.85 1.24 0.809 0.99 0.88 1.13 0.936 1.10 0.240 1.78 0.068 
Serum creatinine* 0.63 0.32 1.23 0.174 0.62 0.22 1.75 0.367 0.66 0.26 1.66 0.370 6.23 1.91 20.30 0.002|| 0.54 0.17 1.72 0.297 1.21 0.157 1.69 0.039 
CMV positive 0.79 0.58 1.08 0.139 0.79 0.49 1.27 0.331 0.80 0.50 1.29 0.360 0.51 0.32 0.81 0.004|| 0.72 0.40 1.29 0.269 1.02 0.223 1.88 0.047 
Allocation type 
(Local/Other) 0.99 0.74 1.31 0.918 0.86 0.55 1.35 0.517 0.88 0.56 1.36 0.560 0.36 0.23 0.56 <0.001|| 0.81 0.48 1.37 0.425 1.12 0.218 1.77 0.057 
Ascites 1.43 1.07 1.90 0.014|| 1.75 1.12 2.74 0.014|| 1.74 1.11 2.73 0.015|| 1.87 1.20 2.90 0.005|| 1.85 1.09 3.14 0.024|| 1.23 0.186 1.66 0.055 
Split donor organ 1.03 0.77 1.37 0.847 1.71 1.11 2.64 0.014|| 1.76 1.14 2.70 0.010|| 0.51 0.34 0.77 0.002|| 1.69 1.08 2.66 0.023|| 2.41 0.551 0.97 0.474 
Portal vein 
thrombosis** 1.65 0.92 2.95 0.094|| 2.34 1.08 5.07 0.032|| 2.31 1.04 5.12 0.040|| 3.63 1.65 7.98 0.001|| 3.35 1.07 10.56 0.039|| 1.01 0.168 1.89 0.024 
Previous abdominal 
surgery** 0.88 0.64 1.20 0.410 1.05 0.64 1.72 0.849 1.06 0.65 1.73 0.820 0.71 0.45 1.12 0.139 1.19 0.67 2.12 0.548 1.01 0.237 1.88 0.052 
Abbreviation: CI (Confidence Interval), LL(Lower Limit), UL(Upper Limit), HR(Hazard Ratio), EST(Estimate). 
* Serum creatinine values were missing for 72 children: 61 alive, 6 retransplanted and 5 dead.
** Both portal vein thrombosis and previous abdominal surgery have missing values in 25 subjects: 23 alive, 1 retransplanted, and 1 dead. 
||Statistically significant at the level of 0.15.
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Table 5. Sensitivity analysis - multivariable analysis 
Cox - Retransplant as event Cox - Retransplant as censor Fine & Gray model RSC - W1 Joint Modeling 
HR 
95% CI 
p-value HR 
95% CI p-
value HR 
95% CI p-
value HR 
95% CI 
p-value HR 
95% CI p-
value 
phi sigma 
LL UL LL UL LL UL LL UL LL UL est 
p-
value est 
p-
value 
Recipient 
age 
1 -- 2 0.84 0.58 1.22 0.373 0.72 0.40 1.31 0.281 0.73 0.39 1.37 0.320 1.48 0.77 2.81 0.236 0.68 0.35 1.33 0.260 
1.06 0.036 1.87 0.001 
> 2 0.74 0.47 1.16 0.191 0.77 0.39 1.56 0.474 0.79 0.39 1.59 0.510 1.37 0.59 3.21 0.466 0.70 0.31 1.56 0.382 
Donor age 0.48 0.32 0.72 <0.001|| 0.71 0.35 1.42 0.332 0.75 0.37 1.53 0.430 1.27 0.58 2.78 0.542 0.81 0.37 1.78 0.603 
Recipient race 
(White/Other) 1.24 0.92 1.66 0.152 0.99 0.63 1.57 0.975 0.97 0.61 1.53 0.880 0.95 0.52 1.72 0.857 0.93 0.55 1.58 0.787 
Bilirubin 0.99 0.97 1.00 0.126 1.01 0.99 1.03 0.524 1.01 0.99 1.03 0.470 0.97 0.94 0.99 0.020|| 1.00 0.98 1.03 0.836 
Serum creatinine * 0.81 0.42 1.59 0.542 0.66 0.22 1.96 0.454 0.68 0.26 1.74 0.420 11.22 2.51 50.10 0.002|| 0.57 0.16 2.02 0.383 
Procurement 
distance 1.00 1.00 1.00 0.895 1.00 1.00 1.00 0.167 1.00 1.00 1.00 0.100 1.00 1.00 1.00 0.393 1.00 1.00 1.00 0.104 
On ventilator 2.18 1.24 3.82 0.007|| 2.52 1.18 5.39 0.017|| 2.47 1.10 5.52 0.028|| 4.26 1.87 9.69 0.001|| 4.20 1.36 12.94 0.013|| 
CMV positive 0.87 0.64 1.20 0.410 0.87 0.54 1.42 0.585 0.88 0.54 1.44 0.610 0.68 0.41 1.14 0.147 0.81 0.45 1.46 0.481 
Allocation type 
(Local/Other) 0.99 0.70 1.40 0.959 0.61 0.36 1.06 0.079 0.61 0.35 1.04 0.067 0.34 0.16 0.71 0.004
|| 0.50 0.25 0.99 0.046|| 
Ascites 1.48 1.09 2.01 0.012|| 1.69 1.04 2.74 0.034|| 1.68 1.02 2.77 0.042|| 1.70 0.97 2.99 0.065 1.99 1.09 3.63 0.026|| 
Split donor organ 1.26 0.87 1.80 0.220 1.72 0.99 3.00 0.053 1.76 1.01 3.05 0.044|| 1.47 0.76 2.84 0.253 1.69 0.89 3.23 0.110 
Portal vein 
thrombosis ** 1.47 0.81 2.66 0.201 2.62 1.19 5.79 0.017
|| 2.69 1.16 6.22 0.021|| 6.29 2.43 16.25 <0.001|| 4.24 1.34 13.37 0.014|| 
Abbreviation: CI (Confidence Interval), LL(Lower Limit), UL(Upper Limit), HR(Hazard Ratio), EST(Estimate). 
* Serum creatinine values were missing for 72 children: 61 alive, 6 retransplanted and 5 dead.
** Portal vein thrombosis has missing values in 25 subjects: 23 alive, 1 retransplanted, and 1 dead. 
||Statistically significant at the level of 0.05.
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4.0  DISCUSSION 
We studied five different models in analyzing marginal posttransplant survival when 
some patients received retransplantats. One of the commonly used approaches is Fine and 
Gray model, which assumes that the main event would never occurs if the competing 
event is observed. Obviously this assumption is not applicable for analyzing 
posttransplantation survival, where recipients may die even after retransplantation. On the 
other hand, patients on the wait list of retransplantation could die due to graft failure or 
other complications. Since the competing events could overtake the occurrence of the 
main event, the RSC method can be applied in this situation. Opposite to the Fine and 
Gray method, the main event and competing event is positively associated in a RSC 
model. Although in our study of posttransplantation survival, the RSC model is more 
suitable than the Fine and Gray model according to the scientific explanation, the results 
of the RSC model were inconsistent with other methods. It could be the performance of 
the IPCW estimators used in the RSC method is only acceptable under low or moderate 
censoring percentage (<35%). Unfortunately, the censoring rate in our data was as high 
as 85.23%. We then devised the joint modeling approach, which was used as the gold 
standard to test the relationship of the main and the competing events. The estimated 
value of φ  was positive but not significant, which indicates that there is no evidence to 
reject the independence claim of the two events. It is worth noting that working with joint 
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modeling could be challenging if one cannot make it convergence, and the model fitting 
is time consuming. Based on the assumption that death and retransplant are independent, 
the Cox PH model treating competing event as censoring was the best choice.   
In conclusion, Fine and Gray model will perform the best if the competing event 
is perfectly negatively associated to the main event. If the events are positively 
associated, the RSC method could the model of choice but only when the censoring 
percentage is below 35%. Meanwhile, the joint modeling approach could be used as a 
standard to verify the relationship between the main and competing events, although it 
may have convergence issue. If unfortunately neither of these models fit well, one may 
choose to fit a Cox PH model treating competing event as censoring.  
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